TransMedics Group (NASDAQ:TMDX) Trading Down 2.6% - Should You Sell?

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report)'s stock price was down 2.6% on Tuesday . The company traded as low as $84.00 and last traded at $84.57. Approximately 112,587 shares were traded during mid-day trading, a decline of 92% from the average daily volume of 1,330,884 shares. The stock had previously closed at $86.84.

Analysts Set New Price Targets

A number of brokerages recently issued reports on TMDX. Canaccord Genuity Group reissued a "buy" rating and set a $104.00 price target on shares of TransMedics Group in a research report on Tuesday, March 11th. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a research note on Wednesday, March 26th. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $122.70.

TransMedics Group Price Performance

The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The firm's fifty day moving average price is $72.48 and its two-hundred day moving average price is $79.44. The stock has a market capitalization of $2.98 billion, a PE ratio of 93.87 and a beta of 2.14.

Hedge Funds Weigh In On TransMedics Group

A number of hedge funds have recently made changes to their positions in TMDX. NBC Securities Inc. purchased a new position in shares of TransMedics Group in the first quarter worth $25,000. Atlas Capital Advisors Inc. purchased a new stake in shares of TransMedics Group during the 4th quarter worth approximately $31,000. Hager Investment Management Services LLC bought a new position in shares of TransMedics Group during the 4th quarter valued at approximately $33,000. Sachetta LLC purchased a new position in shares of TransMedics Group in the fourth quarter valued at $40,000. Finally, AlphaQuest LLC bought a new position in TransMedics Group during the fourth quarter valued at $52,000. Institutional investors own 99.67% of the company's stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.